Zai Lab Ltd
StreetZero Signal 84
About Zai Lab Ltd
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. The company focuses on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in oncology, immunology, neuroscience, and infectious disease. Its goal is to leverage competencies and resources to positively impact human health in China and worldwide.
LATEST FUNDINGPrivate Placement
$249.9M
Announced 2026-11-09
TOTAL RAISED$2.3B
IN THE NEWS
- 🔗 Zai Lab Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 Zai Lab Announces $250 Million Private Placement – Zai Lab Limited
- 🔗 Zai Lab (ZLAB) Jumps 9% on Drug Data & $250M Funding
- 🔗 Zai Lab secures over $100M Series B financing from leading healthcare investors – Zai Lab Limited
- 🔗 Zai Lab Ltd
EMPLOYEES501-1000
FOUNDED2014
HQShanghai, China
Industry
Biotechnology
Tags
BiotechnologyBiopharmaceuticalOncologyCommercial-stage
Investors
Key highlights
- Completed $250M private placement in 2026 to bolster balance sheet for late-stage trials.
- Raised $2.3B total across multiple rounds with backing from leading healthcare investors.
- Focuses on oncology, immunology, neuroscience, and infectious disease with China-US operations.
- Reported positive clinical data driving stock gains alongside the funding announcement.
Ask StreetZero about Zai Lab Ltd
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account